CASI PHARMACEUTICALS TO PARTICIPATE IN THE 2024 H.C. WAINWRIGHT GLOBAL INVESTMENT CONFERENCE
CASI Pharmaceuticals (Nasdaq: CASI) has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 9-11, 2024, at the Lotte New York Palace. Key members of CASI's management team, including CFO Daniel Lang and CMO Alexander Zukiwski, will be available for one-on-one investor meetings during the event.
A pre-recorded corporate presentation will be accessible to conference attendees in 'Virtual Room 1' starting at 7 a.m. Eastern Time on September 9th. Following the conference, the presentation will be made available on the Investors page of CASI's corporate website. This participation underscores CASI's commitment to engaging with investors and showcasing its progress in developing and commercializing innovative therapeutics and pharmaceutical products.
CASI Pharmaceuticals (Nasdaq: CASI) ha annunciato la sua partecipazione al 26° Conferenza annuale globale sugli investimenti di H.C. Wainwright, programmata per il 9-11 settembre 2024, al Lotte New York Palace. I membri chiave del team di gestione di CASI, tra cui CFO Daniel Lang e CMO Alexander Zukiwski, saranno disponibili per incontri one-on-one con gli investitori durante l'evento.
Una presentazione aziendale pre-registrata sarà accessibile ai partecipanti della conferenza nella 'Virtual Room 1' a partire dalle 7:00 ora orientale del 9 settembre. Dopo la conferenza, la presentazione sarà resa disponibile sulla pagina Investitori del sito web aziendale di CASI. Questa partecipazione sottolinea l'impegno di CASI a interagire con gli investitori e a mostrare i suoi progressi nello sviluppo e nella commercializzazione di terapie innovative e prodotti farmaceutici.
CASI Pharmaceuticals (Nasdaq: CASI) anunció su participación en la 26ª Conferencia Anual Global de Inversiones de H.C. Wainwright, programada para el 9-11 de septiembre de 2024, en el Lotte New York Palace. Miembros clave del equipo directivo de CASI, incluidos CFO Daniel Lang y CMO Alexander Zukiwski, estarán disponibles para reuniones individuales con inversores durante el evento.
Una presentación corporativa pregrabada estará accesible para los asistentes a la conferencia en la 'Sala Virtual 1' a partir de las 7 a.m. hora del Este el 9 de septiembre. Después de la conferencia, la presentación se pondrá a disposición en la página de Inversores del sitio web corporativo de CASI. Esta participación subraya el compromiso de CASI de interactuar con los inversores y mostrar su progreso en el desarrollo y la comercialización de terapias innovadoras y productos farmacéuticos.
CASI Pharmaceuticals (Nasdaq: CASI)는 2024년 9월 9-11일에 Lotte New York Palace에서 개최되는 H.C. Wainwright 제26회 연례 글로벌 투자 컨퍼런스에 참여한다고 발표했습니다. CFO Daniel Lang과 CMO Alexander Zukiwski를 포함한 CASI의 주요 관리 팀은 행사 기간 동안 투자자들과의 일대일 회의에 참석할 수 있습니다.
사전 녹화된 기업 발표는 9월 9일 동부 표준시 오전 7시부터 '가상 방 1'에 참석하는 참석자들에게 제공될 것입니다. 컨퍼런스 종료 후, 발표는 CASI의 기업 웹사이트 투자자 페이지에 제공될 것입니다. 이 참여는 투자자와의 소통 및 혁신적인 치료법과 제약 제품 개발 및 상용화에 대한 CASI의 발전을 선보이려는 약속을 강조합니다.
CASI Pharmaceuticals (Nasdaq: CASI) a annoncé sa participation à la 26ème Conférence Annuelle Globale sur les Investissements de H.C. Wainwright, prévue du 9 au 11 septembre 2024, au Lotte New York Palace. Des membres clés de l'équipe de direction de CASI, y compris CFO Daniel Lang et CMO Alexander Zukiwski, seront disponibles pour des réunions individuelles avec les investisseurs pendant l'événement.
Une présentation d'entreprise préenregistrée sera accessible aux participants de la conférence dans la 'Salle Virtuelle 1' à partir de 7 heures, heure de l'Est, le 9 septembre. Après la conférence, la présentation sera mise à disposition sur la page Investisseurs du site web de CASI. Cette participation souligne l'engagement de CASI à interagir avec les investisseurs et à montrer ses progrès dans le développement et la commercialisation de thérapeutiques novatrices et de produits pharmaceutiques.
CASI Pharmaceuticals (Nasdaq: CASI) hat seine Teilnahme an der 26. jährlichen globalen Investorenkonferenz von H.C. Wainwright angekündigt, die vom 9. bis 11. September 2024 im Lotte New York Palace stattfindet. Wichtige Mitglieder des Management-Teams von CASI, darunter CFO Daniel Lang und CMO Alexander Zukiwski, stehen während der Veranstaltung für persönliche Investorengespräche zur Verfügung.
Eine vorab aufgezeichnete Unternehmenspräsentation wird den Konferenzteilnehmern ab dem 9. September um 7 Uhr Eastern Time in 'Virtual Room 1' zur Verfügung stehen. Nach der Konferenz wird die Präsentation auf der Investoren-Seite der Unternehmenswebsite von CASI zur Verfügung gestellt. Diese Teilnahme unterstreicht CASIs Engagement für die Interaktion mit Investoren und die Präsentation seiner Fortschritte bei der Entwicklung und Commercialisierung innovativer Therapeutika und pharmazeutischer Produkte.
- None.
- None.
A pre-recorded corporate presentation will be available for conference participants to view in "Virtual Room 1" at 7 a.m. Eastern Time on September 9th. Thereafter, the presentation will be available on the Investors page of the CASI corporate website at https://casipharmaceuticals.com/investor.html.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in
COMPANY CONTACT:
Rui Zhang
CASI Pharmaceuticals, Inc.
240.864.2643
ir@casipharmaceuticals.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/casi-pharmaceuticals-to-participate-in-the-2024-hc-wainwright-global-investment-conference-302237656.html
SOURCE CASI Pharmaceuticals
FAQ
When is CASI Pharmaceuticals (CASI) participating in the H.C. Wainwright Global Investment Conference?
Where can investors view CASI's corporate presentation after the conference?
Which CASI Pharmaceuticals executives will be available for investor meetings at the conference?
What time will CASI's pre-recorded presentation be available on September 9th, 2024?
